PT2356090T - Crystalline forms of fingolimod hcl - Google Patents

Crystalline forms of fingolimod hcl

Info

Publication number
PT2356090T
PT2356090T PT97483507T PT09748350T PT2356090T PT 2356090 T PT2356090 T PT 2356090T PT 97483507 T PT97483507 T PT 97483507T PT 09748350 T PT09748350 T PT 09748350T PT 2356090 T PT2356090 T PT 2356090T
Authority
PT
Portugal
Prior art keywords
crystalline forms
fingolimod hcl
fingolimod
hcl
crystalline
Prior art date
Application number
PT97483507T
Other languages
Portuguese (pt)
Inventor
Mutz Michael
Jordine Guido
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2356090T publication Critical patent/PT2356090T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT97483507T 2008-11-11 2009-11-10 Crystalline forms of fingolimod hcl PT2356090T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11

Publications (1)

Publication Number Publication Date
PT2356090T true PT2356090T (en) 2017-10-16

Family

ID=40521487

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97483507T PT2356090T (en) 2008-11-11 2009-11-10 Crystalline forms of fingolimod hcl

Country Status (14)

Country Link
US (2) US8530522B2 (en)
EP (1) EP2356090B1 (en)
JP (4) JP2012508216A (en)
KR (2) KR101393994B1 (en)
CN (3) CN102209705A (en)
AU (1) AU2009315736B2 (en)
BR (1) BRPI0921826A2 (en)
CA (1) CA2743232C (en)
ES (1) ES2643161T3 (en)
MX (1) MX2011004962A (en)
PL (1) PL2356090T3 (en)
PT (1) PT2356090T (en)
RU (2) RU2549899C2 (en)
WO (1) WO2010055028A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228617A (en) * 2010-10-01 2013-07-31 斯索恩有限公司 Process for making fingolimod hydrochloride crystals
EP2632889B1 (en) 2010-10-28 2018-08-29 Mapi Pharma Limited Intermediate compounds and process for the preparation of fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
ES2746016T3 (en) 2010-12-28 2020-03-04 Synthon Bv Procedure for the preparation of fingolimod hydrochloride crystals
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
US9216943B2 (en) 2011-04-29 2015-12-22 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
DK2809318T3 (en) 2011-05-26 2019-07-22 Gri Bio Inc Ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
US9751834B2 (en) 2011-05-26 2017-09-05 Gri Bio, Inc. Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
CA2887385C (en) 2011-05-26 2017-01-10 Glycoregimmune, Inc. Carrying On Business As Gri Bio, Inc. Hydroxy-substituted amino and ammonium derivatives and their medical use
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (en) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 Method for preparing fingolimod mucate and crystals thereof and application of fingolimod mucate and crystals thereof
AU2014206588A1 (en) * 2013-01-17 2015-07-23 Shilpa Medicare Limited Process for preparation of Fingolimod and its salts
EP2964210B1 (en) * 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (en) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Crystalline h-modification of 2-amino-2-(2-(4-octylphenyl) ethyl)propane-1,3-diole hydrochloride, method for its production and pharmaceutical composition based thereon
CN106860440A (en) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 Application of the fingolimod hydrochloride in systemic lupus erythematosus encephalopathic medicine is prepared
CN106667981B (en) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 Fingolimod hydrochloride is preparing the application in medicine physical property liver injury medicament
GR1009654B (en) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Pharmaceutical composition comprising an immunomodulatory agent and method for the preparation thereof
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20240262783A1 (en) 2021-05-31 2024-08-08 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (en) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical COMPOSED OF 2-AMINO-1,3-PROPANODIOL AND IMMUNOSUPPRESSOR.
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP4079505B2 (en) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 Novel process for the preparation of 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol
WO2000027798A1 (en) * 1998-11-11 2000-05-18 Novartis Ag Production of 2-amino-2-[2-(4-c2-20-alkyl-phenyl)ethyl]propane-1,3-diols
ES2173679T3 (en) * 1999-01-27 2002-10-16 Idea Ag IMMUNIZATION / TRANSNASAL TRANSPORTATION WITH HIGHLY ADAPTABLE VEHICLES.
AU2460600A (en) * 1999-02-10 2000-08-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
CN1144779C (en) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein
CA2445605A1 (en) * 2001-06-08 2002-12-19 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
DK1505959T3 (en) * 2002-05-16 2009-02-23 Novartis Ag Use of EDG receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
PL1613288T3 (en) * 2003-04-08 2009-07-31 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
CN1212308C (en) * 2003-07-24 2005-07-27 漆又毛 Process for preparing amino-2-(2-(4-otylphenyl) ethyl)-1, 3-propylene glycol hydrochloride
CN1241903C (en) * 2003-10-14 2006-02-15 马启明 Method for preparing 2-para octylphenyl ehtyl-2-amino propanediol
TWI418350B (en) * 2005-06-24 2013-12-11 Sankyo Co Use of pharmaceutical compositions comprising ppar modulator
AU2006297130B2 (en) * 2005-09-30 2009-12-24 Novartis Ag DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection
AU2006307939B2 (en) * 2005-10-26 2012-03-29 Merck Serono Sa Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN1310869C (en) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method
CN100548968C (en) * 2006-03-01 2009-10-14 徐州师范大学 A kind of method for preparing 2-to octyl group styroyl-2-amino-propanediol hydrochloride
US8318812B2 (en) * 2006-06-02 2012-11-27 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
ES2748432T3 (en) * 2006-09-26 2020-03-16 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
KR20160131126A (en) * 2008-06-20 2016-11-15 노파르티스 아게 Paediatric compositions for treating multiple sclerosis
CN103228617A (en) 2010-10-01 2013-07-31 斯索恩有限公司 Process for making fingolimod hydrochloride crystals

Also Published As

Publication number Publication date
JP2012508216A (en) 2012-04-05
JP2014139179A (en) 2014-07-31
US20140051766A1 (en) 2014-02-20
RU2015111229A (en) 2015-11-20
EP2356090B1 (en) 2017-07-05
AU2009315736B2 (en) 2013-08-29
WO2010055028A2 (en) 2010-05-20
RU2011123371A (en) 2012-12-20
CA2743232A1 (en) 2010-05-20
KR20110069156A (en) 2011-06-22
CA2743232C (en) 2015-12-29
EP2356090A2 (en) 2011-08-17
US20110229501A1 (en) 2011-09-22
PL2356090T3 (en) 2017-12-29
CN107233336A (en) 2017-10-10
CN102209705A (en) 2011-10-05
WO2010055028A3 (en) 2010-07-08
RU2549899C2 (en) 2015-05-10
US8530522B2 (en) 2013-09-10
JP2016028056A (en) 2016-02-25
BRPI0921826A2 (en) 2016-01-12
JP2018035160A (en) 2018-03-08
CN104788325A (en) 2015-07-22
ES2643161T3 (en) 2017-11-21
KR20130109254A (en) 2013-10-07
AU2009315736A1 (en) 2010-05-20
MX2011004962A (en) 2011-05-30
KR101393994B1 (en) 2014-05-14
RU2015111229A3 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PL2356090T3 (en) Crystalline forms of fingolimod hcl
HK1254977A1 (en) Crystalline form of sofosbuvir
IL212073A0 (en) Salts of fingolimod
GB0819182D0 (en) Crystalline forms
PL2262793T3 (en) Nilotinib hci crystalline forms
ZA201105462B (en) Crystalline insulin-conjugates
IL210322A (en) Crystalline form of sitagliptin malate
GB201001075D0 (en) Crystalline forms
EP2477628A4 (en) Preparation of crystalline forms of dihydropyrazolopyrimidinone
IL216648A0 (en) Crystalline forms of febuxostat
PT2963024T (en) Crystalline methylthioninium chloride hydrates - part 2
EP2365821A4 (en) Crystalline form of linaclotide
GB0902406D0 (en) Crystalline polymorphic form
ZA201202405B (en) Crystallization of 4'-epidaunorubicin x hci
SI2303866T1 (en) Crystalline forms of rabeprazole sodium
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
IL200126A (en) Process for obtaining the crystalline form v of agomelatine
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL205451A0 (en) Crystalline forms of tigecycline hydrochloride
EP2160376A4 (en) Novel crystalline forms of atovaquone
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
IL205857A0 (en) Processes for preparation of crystalline tigecyclline form ii
AU2013100530B4 (en) Crystalline forms of fingolimod HCL
HU0800755D0 (en) Novel crystalline forms
IL213288A0 (en) Crystalline forms